

The current survival rate of Idiopathic Pulmonary Fibrosis (IPF) is as low as some of the most devastating cancers. Thanks to research, recent advances in new treatments are helping to slow the progression of the disease in some cases. While this is promising, more research is desperately needed to better understand this complex disease so we can drive further progress of treatments, improve the late rate of diagnosis, support psychological management and search for a cure.
Lung Foundation Australia is committed to driving dedicated research that will help improve the health outcomes and quality of life for those affected by IPF. Our research program includes a world renowned IPF registry, clinical trials group and a suite of IPF research awards and grants.
Pulmonary Fibrosis Australasian Clinical Trials Network (PACT)
Our Australian Idiopathic Pulmonary Fibrosis (IPF) Registry is a unique research platform that collects information on patients living with IPF to better understand this rare and complex disease. To improve our understanding, participants generously contribute information about their health regularly so that it can be used to undertake a wide range of research projects.
Our researchers

Treatment & models of care
Idiopathic Pulmonary Fibrosis
Immune regulation of Idiopathic Pulmonary Fibrosis
Make a difference with research
Our ability to deliver Idiopathic Pulmonary Fibrosis research relies on the generosity and support of organisations and individual donors. Every extra dollar ensures more vital research is undertaken.